Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rick Olesinski

Physician Assistant Avondale, AZ Physician Assistant

NPI 1093764672 CMS profile 11018582

10450 W McDowell Rd Ste 102, Avondale, AZ 85392

Open in the dashboard

General payments

$3,719

35 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rick Olesinski of Avondale, AZ is reported in the CMS Open Payments database as having received $3,719 across 35 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $999 12
2024 General $417 7
2023 General $162 3
2022 General $2,128 12
2021 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rick Olesinski
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Rick Olesinski were reported at $999. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Rick Olesinski Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $13 $132 $37–$438 $132
2022 $2,128 $155 $48–$522 $149
2023 $162 $167 $52–$557 $160
2024 $417 $178 $55–$600 $164
2025 $999 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Stryker Corporation $3,484 29 payments
  2. Pacira Pharmaceuticals Incorporated $123 1 payment
  3. Vertex Pharmaceuticals Incorporated $27 1 payment
  4. Ethicon US, LLC $25 1 payment
  5. DePuy Synthes Sales Inc. $22 1 payment
  6. Boston Scientific Corporation $22 1 payment
  7. Bioventus LLC $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $2,356 9 payments
  2. Food and Beverage $1,363 26 payments
Products named General payments · program years 2021–2025
  1. MAKO $2,369 10 payments
  2. AEQUALIS $847 15 payments
  3. INSIGNIA $254 1 payment
  4. TRIATHLON $254 1 payment
  5. ZIPSEAL 16 SURGICAL SKIN CLOSURE KIT $159 1 payment
  6. Iovera $123 1 payment
  7. ACCOLADE $110 3 payments
  8. JOURNAVX $27 1 payment
  9. ETHICON $25 1 payment
  10. DERMABOND $25 1 payment
  11. Other $59 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

931

Median for Physician Assistant: 241

Drug cost

$6,998

Median for Physician Assistant: $4,110

Branded share of claims

17.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 137 $2,728
Oxycodone Hcl Generic 379 $2,267
Morphine Sulfate Er Morphine Sulfate Brand 131 $613
Methylprednisolone Generic 44 $307
Hydromorphone Hcl Generic 45 $277
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 17 $196
Meloxicam Generic 49 $135
Diclofenac Sodium Generic 16 $121
Ondansetron Odt Ondansetron Brand 15 $98
Tramadol Hcl Generic 28 $89

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$53,328

Of which drugs: $22,453

Medicare patients

235

Average age 75

Services billed

2,752

147 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 31%
Depression 26%
Ischemic heart disease 25%
Diabetes 20%
Atrial fibrillation 17%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 36 40 $21,468
Injection, methylprednisolone acetate, 1 mg J1010 Office 33 1,840 $187

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record